红色生物技术市场规模、份额、成长分析（按产品、最终用户和地区）- 产业预测，2025 年至 2032 年

2023 年全球红色生物技术市场价值为 5,200 亿美元，预计将从 2024 年的 5,527.6 亿美元成长到 2032 年的 9,011.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.3%。

在感染疾病和新兴感染疾病日益普及的推动下，全球红色生物技术市场正在显着扩张。这种激增给医疗保健系统带来了巨大的压力，迫使它们寻找新颖有效的治疗方案，从而导致对单株抗体、重组蛋白和基因疗法等先进生物製药的需求不断增长。作为回应，製药和生物技术产业正在大力投资研发以推动创新。此外，基因组定序和生物资讯学的进步使得开发针对个人基因特征的个人化治疗方法成为可能，从而使市场呈现个人化医疗的趋势。因此，从传统治疗方法向精准标靶治疗的转变正在推动市场成长，并凸显诊断和基因标靶治疗的市场模式。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 重大投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 技术分析

全球红色生物技术市场规模（依产品及复合年增长率） （2025-2032 年）

• 市场概览
• 单株抗体
• 多株抗体
• 重组蛋白
• 疫苗
• 细胞免疫疗法产品
• 基因治疗产品
• 细胞治疗产品
• 组织工程产品
• 干细胞
• 细胞培养
• 病毒载体
• 酵素
• 套件和试剂
• 动物模型
• 分子诊断
• 其他的

全球红色生物技术市场规模（按最终用户和复合年增长率） （2025-2032 年）

• 市场概览
• 学术研究机构
• 合约行销/合约风险评估
• 製药和生物技术公司
• 其他的

全球红色生物技术市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Amgen Inc.
• Gilead Sciences, Inc.
• Biogen
• Pfizer Inc.
• Novartis AG
• Hoffmann-La Roche
• Johnson & Johnson Services, Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• GSK plc.
• AstraZeneca
• Eli Lilly and Company
• Novo Nordisk A/S
• Bayer AG
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• Astellas Pharma Inc.

结论和建议

Global Red Biotechnology Market size was valued at USD 520.0 billion in 2023 and is poised to grow from USD 552.76 billion in 2024 to USD 901.16 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).

The global red biotechnology market is experiencing significant expansion driven by the increasing prevalence of chronic and emerging infectious diseases. This surge creates intense pressure on healthcare systems to find novel and efficient therapeutic solutions, leading to heightened demand for advanced biopharmaceuticals such as monoclonal antibodies, recombinant proteins, and gene therapies. In response, the pharmaceutical and biotech sectors are channeling substantial investments into research and development, fostering innovation. Additionally, the trend towards personalized medicine is shaping the market, as advancements in genomic sequencing and bioinformatics enable the creation of tailored treatments that align with individual genetic profiles. Consequently, this shift from conventional therapies to precision-targeted drugs enhances market growth, highlighting opportunities for diagnostics and gene-targeted therapies within the red biotechnology landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Red Biotechnology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Red Biotechnology Market Segments Analysis

Global Red Biotechnology Market is segmented by Product, End-User and region. Based on Product, the market is segmented into Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products, Gene Therapy Products, Cell Therapy Products, Tissue-Engineered Products, Stem Cells, Cell Culture, Viral Vector, Enzymes, Kits and Reagents, Animal models, Molecular diagnostics and Others. Based on End-User, the market is segmented into Academic Research Institutes, CMOs & CROs, Pharmaceutical & Biotechnology Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Red Biotechnology Market

The global red biotechnology market is experiencing significant growth due to the rising demand for personalized medicine. Innovations in genomics and diagnostics facilitate the creation of customized treatments that cater to the unique genetic profiles of individuals. Such advancements have paved the way for the development of more effective therapeutic options, including targeted therapies and gene treatments, ultimately improving patient outcomes. As healthcare shifts towards more individualized approaches, the emphasis on precision in medical interventions continues to propel the expansion of the red biotechnology sector, highlighting its pivotal role in advancing modern medicine and enhancing the quality of patient care.

Restraints in the Global Red Biotechnology Market

The substantial expenses linked to the development of red biotechnology products, especially gene therapies and biologics, present a notable challenge within the market. The financial burden of research, clinical trials, and manufacturing processes often restricts the ability of smaller biotech firms to compete effectively. This high cost structure can hinder market expansion, particularly in emerging economies where financial limitations are more pronounced. As a result, the potential for innovation and growth within the industry may be stifled, ultimately affecting the overall advancement and accessibility of red biotechnology solutions on a broader scale.

Market Trends of the Global Red Biotechnology Market

The global red biotechnology market is witnessing a significant surge, propelled by groundbreaking advancements in gene and cell therapies, notably through innovative technologies such as CRISPR and other gene editing tools. This evolution is not only revolutionizing the treatment landscape for genetic disorders but is also paving the way for personalized medicine, thereby enhancing patient outcomes across multiple medical sectors, particularly in oncology. With increasing investments in research and development and a growing number of clinical trials, the demand for targeted therapies is escalating, making red biotechnology a critical component of future healthcare strategies, poised for substantial growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Analysis

Global Red Biotechnology Market Size by Product & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Proteins
• Vaccines
• Cell-Based Immunotherapy Products
• Gene Therapy Products
• Cell Therapy Products
• Tissue-Engineered Products
• Stem Cells
• Cell Culture
• Viral Vector
• Enzymes
• Kits and Reagents
• Animal models
• Molecular diagnostics
• Others

Global Red Biotechnology Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Academic Research Institutes
• CMOs & CROs
• Pharmaceutical & Biotechnology Companies
• Others

Global Red Biotechnology Market Size & CAGR (2025-2032)

• North America (Product, End-User)
  • US
  • Canada
• Europe (Product, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations